Cuprina Holdings, a biomedical company specializing in chronic wound management and cosmeceuticals, has announced the pricing of its initial public offering at $4.00 per share. The firm commitment offering includes 3,000,000 Class A Ordinary Shares, aiming to raise $12 million.

Vertex Pharmaceuticals is poised to announce its first-quarter earnings for 2025 after the market closes on Monday, May 5th. Analysts project robust financial results, anticipating earnings of $4.24 per share and revenue of $2.85 billion. The company has also set its fiscal year 2025 guidance at earnings per share.

Genmab announces plans to submit a supplemental Biologics License Application to the FDA for a combination therapy targeting relapsed or refractory follicular lymphoma, potentially offering new hope to patients.

Coloplast A/S has updated its financial guidance for the fiscal year 2024/25 and pre-announced key financial figures for the first half of the year. This significant move signals important developments for investors and stakeholders alike.

Bank of America Global Research forecasts that the mass adoption of humanoid robots will commence in 2028, potentially revolutionizing industries worldwide. By 2060, they predict an astounding three billion humanoid robots could be in ownership globally, marking a significant shift towards automation and technological integration.

A research team has unveiled a novel method for isolating high-purity muscle stem cells from pig tissue, a breakthrough that could enhance the production of cultured meat.

Algorized, a pioneering deep tech startup specializing in people-sensing AI, has joined the prestigious MassRobotics startup community. This partnership aims to redefine the future of human-machine interaction through advanced sensor fusion technology.

Promising advances in immunotherapy may allow some cancer patients to bypass chemotherapy, radiation, and surgery. New clinical trial findings reported by Dr. Jon LaPook suggest a groundbreaking shift in cancer treatment, offering renewed hope to many.

Photocure ASA presented new studies at the AUA2025 conference highlighting how Blue Light Cystoscopy (BLC) improves the detection and risk stratification of bladder cancer, aiding in more informed treatment decisions.

Microplastics have been discovered in the large neck arteries that supply blood to the brain, with stroke survivors showing the highest levels of accumulation, according to a recent small study.

CG Oncology, a small biotech firm rivaling Johnson & Johnson, saw its stock soar 44% following promising clinical trial results for its bladder cancer drug. The breakthrough has drawn significant investor attention and could signal a shift in cancer treatment options.

As one of 300 publicly-traded companies in its industry, Metagenomi (NASDAQ: MGX) faces stiff competition. We delve into how it measures up against its peers in key financial metrics.

The U.S. Transportation Department is taking steps to remove regulatory hurdles for automakers, aiming to foster innovation in autonomous vehicle technology and compete with China. This initiative seeks to accelerate development in the self-driving car industry by streamlining regulations that have previously hindered progress.

Actuate Therapeutics is set to present the topline results of its Phase 2 trial of elraglusib at the 2025 American Society of Clinical Oncology Annual Meeting. The oral presentation will focus on the combination of elraglusib with gemcitabine/nab-paclitaxel in the first-line treatment of metastatic pancreatic ductal adenocarcinoma.

Global agriculture faces mounting waste disposal challenges and the threat of antibiotic resistance. Mushroom-based composting emerges as a promising solution to improve waste degradation, reduce pathogens, and curb the spread of antibiotic resistance genes, safeguarding agricultural safety and the environment.

Robles BioCeutics has appointed renowned drug developer and healthcare entrepreneur Dr. Radu Pislariu to its Scientific Advisory Board. This strategic move comes as the company gears up for clinical trials in regenerative dermatology.

A rising number of dogs are silently suffering from gut health issues. WildGut introduces a groundbreaking fruit seed detox to address the root causes and restore canine vitality with a simple, once-a-day chew.

Hammer Missions, a London-based AI company specializing in drone inspections of built structures, has raised €1.6 million to accelerate its technology development and expand into North America.

Three teenagers have developed the Thermavault, a salt-powered refrigerator that operates without electricity. They’re set to build 200 units for hospitals, aiming to keep vaccines cool with a reusable salt solution.

Twenty exceptional Georgia Tech students have received NSF Graduate Research Fellowships, securing significant funding for their advanced studies in STEM fields. The fellowships, valued at $159,000 each, support three years of graduate study and tuition.

Duchesnay Pharmaceutical Group has established an Advisory Board comprising five external experts. This strategic move aims to leverage their diverse experience to guide the company’s continued growth and success.